Novel Thrombolytic Drug Based on Thrombin Cleavable Microplasminogen Coupled to a Single-Chain Antibody Specific for Activated GPIIb/IIIa.

J Am Heart Assoc · 2017 · PMC5523756 · PMID 28159824

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Urokinase at the therapeutic dose established in a previous study (500 U/g BW 23 ) resulted in a highly significant increase in bleeding time, even higher than the prolongation obtained with 12 μg/g BW doses of the HtPlg constructs.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.